Browse studies

Find your next paid study

816 recruiting studies matching your filters

A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)

The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people wi…

NSCLCNSCLC, Stage INSCLC Stage II+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07323732

Observational

Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)

This proposal aims to determine the effects of tVNS on autonomic tone, atrial substrate and neuromodulators in patients with paroxysmal atrial fibrillation (AF…

Paroxysmal Atrial Fibrillation

Estimated

~$10 – $6,250

University of OklahomaNCT05172765

Phase 1

Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies

This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarab…

B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more

Estimated

~$10 – $6,250

Phase 2

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in co…

Plasma Cell Myeloma Refractory

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP l…

Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more

Estimated

~$10 – $8,750

Tango Therapeutics, Inc.NCT06810544

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource…

Non Small Cell Lung CancerLung Cancer MetastaticLung Cancer, Nonsmall Cell+1 more

Estimated

~$10 – $1,125

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT05537922

Phase 3

The Use of Nasogastric Tubes And Water-Soluble Contrast In The Management Of Small Bowel Obstruction: A Feasibility Study

Small bowel obstruction (SBO) is one of the most common causes of serious gastrointestinal disease in the US. Adhesion-related SBO (aSBO) is usually treated by…

Adhesive Small Bowel Obstruction

Estimated

~$10 – $6,250

University of California, Los AngelesNCT06182319

Phase 1

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies …

Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)+4 more

Estimated

~$10 – $8,750

GV20 TherapeuticsNCT05669430

Phase 2

Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL)

This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chr…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Estimated

~$10 – $6,250

University of UtahNCT05183854

Observational

An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)

In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).

Colorectal Cancer Liver Metastases (CRLM)Small Future Liver Remnant (FLR)

Estimated

~$10 – $6,250

Maastricht UniversityNCT05428735

Phase 2

A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopo…

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdult T-Cell Leukemia/Lymphoma+14 more

Estimated

~$10 – $6,250

Thomas Jefferson UniversityNCT05031897

Phase 1

A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders

The purpose of this study is to look at the safety, tolerability, and serum concentration of daratumumab administered subcutaneously in the thigh versus the ab…

Plasma Cell Disorder

Estimated

~$10 – $6,250

University of Maryland, BaltimoreNCT07075510